




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 9/58, 9/60, 9/62</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/27370 (43) International Publication Date: 18 May 2000 (18.05.00)</p>
<p>(21) International Application Number: PCT/US99/25604 (22) International Filing Date: 1 November 1999 (01.11.99) (30) Priority Data: 09/187,319 6 November 1998 (06.11.98) US (71) Applicant: ANDRX PHARMACEUTICALS, INC. [US/US]; Suite 201, 4001 S.W. 47th Avenue, Fort Lauderdale, FL 33314 (US). (72) Inventors: CHEN, Chih-Ming; 10680 S.W. 40th Manor, Davie, FL 33328 (US). CHENG, Xiu, Xiu; 3150 W. Rolling Hills, Davie, FL 33328 (US). (74) Agent: COSTIGAN, James, V.; Hedman, Gibson & Costigan, P.C., 1185 Avenue of the Americas, New York, NY 10036 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>

(54) Title: CONTROLLED RELEASE FORMULATION FOR WATER SOLUBLE DRUGS



○ 0.1N HCl △ pH 7.5

(57) Abstract

A once-a-day controlled release diltiazem formulation comprises: (a) 20–50 wt.% of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer consisting essentially of diltiazem and polymeric binder; and a second layer which comprises a membrane comprising a pH dependent polymeric material; and (b) 50–80 wt.% of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core comprising a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a polymeric binder and a second layer which comprises a polymeric membrane and an alkaline earth metal stearate which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to diltiazem, and (c) a unit dose containment system.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONTROLLED RELEASE FORMULATION FOR WATER SOLUBLE DRUGS

BACKGROUND OF THE INVENTION:

5 The present invention relates to controlled
release unit dose formulations of water soluble drugs
in general which are exemplified by diltiazem
hydrochloride (diltiazem). There is a need for a
means for varying the release rates of water soluble
10 drugs from multiparticulate beads which have release
membranes that are applied by a coating process.
Diltiazem is sold commercially in extended release
pharmaceutical dosage forms in order to maintain a
therapeutic serum level of diltiazem and to minimize
15 the effects of missed doses of drugs caused by a lack
of patient compliance. The minimum therapeutic plasma
diltiazem concentrations are in the range of 50 to
200 ng/ml.

Cardizem® CD is described as a once-a-day
extended release capsule containing diltiazem and
20 fumaric acid. In the file history of U.S. 5,286,497,
representations were made that the formulation
disclosed in that patent is the formulation for
Cardizem® CD. The formulation for Cardizem® CD is
25 identified in the file history of U.S. 5,286,497 as
having a "stair-step release profile" which has a
rapid release bead and an extended release bead.

U.S. 5,567,441 also discloses a formulation
of diltiazem which is bioequivalent to Cardizem CD
but has a different release profile in hydrochloric
30 acid. That formulation exhibits a slower in vitro
release profile in 0.1N hydrochloric acid than the
slow release bead of the present invention but
exhibits substantially the same in vivo release
profile.

35 In U.S. 5,229,135 and in U.S. 5,529,791,
once-a-day formulations are described that are based
on a single pellet which is prepared with an active

core which is coated with diltiazem and an inner and outer membrane. Other diltiazem formulations are disclosed in U.S. 4,721,619; U.S. 4,894,240; U.S. 5,002,776; U.S. 5,364,620; 4,891,230; U.S. 4,917,899; 5 U.S. 5,288,505; and U.S. 5,336,504.

The present invention provides novel water soluble pharmaceutical formulations which are two-pellet based capsule formulations. The diltiazem formulations made according to the present invention do not have a "stair-step release profile" but do 10 provide a "two-peak pharmacokinetic profile". Moreover, the diltiazem formulations of the present invention does not require the presence of fumaric acid or any other organic acid in the core. The 15 present invention also provides a means for varying the release rates of water soluble to allow for faster in vitro release of the drug.

SUMMARY OF THE INVENTION

20

The present invention is directed to a once-a-day controlled release water soluble pharmaceutical formulation which comprises:

- 25 (a) from 20 to 50% by weight of polymeric enteric coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a polymeric binder; and a second layer which comprises a membrane 30 comprising a polymeric enteric coating material; and
- (b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a 35 biologically inert core which is coated with a combined first layer which consists essentially of a water soluble drug and a polymeric binder and a second layer which comprises a polymeric membrane and

an alkaline earth metal stearate said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to said water soluble drug; and
5 (c) a unit dose containment system.

The present invention also provides a dosage form of diltiazem which exhibits in 0.1N HCl, a release rate profile which is initially a relatively slow, zero order release rate that continues for up to about 12-14 hours. Thereafter, there is a sharp increase in the rate of release which can be characterized as a delayed pulse.
10

It is surprising and unexpected that the combined zero order-delayed pulse in vitro release characteristics of the diltiazem dosage form of the present invention provides substantially the same in vivo "two peak" plasma levels of diltiazem which is provided by a commercial formulation which exhibits in vitro a stair-step type of release profile.
15
20

It is an object of the invention to provide a once-a-day water soluble drug dosage system.

It is also an object of the present invention to provide a once-a-day water soluble drug dosage system which is free of any organic acid component.
25

It is also an object of this invention to provide an organic acid free, once-a-day diltiazem dosage system which is therapeutically or biologically equivalent to a once-a-day stair step diltiazem dosage system which contains an organic acid.
30

It is also an object of this invention to provide a once a day diltiazem dosage system which is bioequivalent to Cardizem CD but has a different in vitro release profile when the release profile is
35

determined in 0.1N hydrochloric acid.

These and other objects of the invention will become apparent from the appended specification.

5

BRIEF DESCRIPTION OF THE DRAWINGS

10 FIG. 1 is a graph which shows the in vitro dissolution rate of diltiazem delayed pulse membrane coated core pellets prepared according to Example 1 of the present invention in 0.1N HCl using a USP Type II apparatus at 37°C and 100rpm and simulated intestinal fluid (pH 7.5) using a USP Type II
15 apparatus at 37°C and 75rpm .

20 FIG. 2 is a graph which shows the in vitro dissolution rate of diltiazem delayed pulse membrane coated core pellets prepared according to Example 2 of the present invention in 0.1N HCl and simulated intestinal fluid (pH 7.5) using a USP Type II apparatus at 37°C and 100rpm.

25 FIG. 3 is a graph which shows the in vitro dissolution rate of diltiazem delayed pulse membrane coated core pellets prepared according to Comparative Example 3 of the present application in 0.1N HCl and simulated intestinal fluid (pH 7.5) using a USP Type II apparatus at 37° C and 100rpm.

30

FIG. 4 is a graph which shows a plot of the mean plasma diltiazem concentrations versus time, of a diltiazem formulation prepared according to Example 1 with the points shown by circles and a plot of the mean diltiazem concentrations of Cardizem CD where
35 the reference points are shown by squares.

DETAILED DESCRIPTION OF THE INVENTION

The once-a-day, controlled release formulation for water soluble drugs provides an alternative to prior art formulations for once-a-day dosing of drugs that are to be maintained at a steady state level in the blood plasma.

Suitable water soluble drugs which are useful in the dosage formulation of the present invention include diltiazem hydrochloride, verapamil hydrochloride, bupropion hydrochloride, metformin hydrochloride, propranolol hydrochloride, dextromethorphan hydrobromide, diphenhydramine hydrochloride, disopyramide hydrochloride, tramadol, fluoxetine hydrochloride, paroxetine hydrochloride, pentoxifylline hydrochloride and the like.

Both the enteric polymer membrane coated pellet and the delayed pulse polymer membrane coated pellet are based on an active core which contains the diltiazem hydrochloride. The core is made by coating a biologically inactive core component such as non-pareil sugar particles i.e., sugar spheres NF, starch granules, clay particles or other material on which may be deposited a coating of diltiazem hydrochloride in combination with a polymeric binder which comprises from 5 to 10wt% (based on the combined weight of the binder and the diltiazem). The binder can be any pharmaceutically acceptable binding agent known to the art such as ethylcellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose and hydroxypropylcellulose. The binder is applied using conventional solvents which are removed from the product during processing.

The active core component is provided with an enteric coating which is a polymeric enteric coating material to form a rapid release bead. The enteric coatings are "pH dependent" which describes

the well known effect of an enteric coating which prevents release of the dosage form in the low pH conditions of the stomach but permits release in the higher pH conditions of the small intestine. The enteric coating will comprise from 4 to 15% preferably from 5 to 11% by weight based on the combined weight of the active core component and the total weight of the coating. The enteric coating polymer may be selected from the group consisting of shellac, methacrylic acid copolymers, (Eudragit S or L) cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate trimellitate and polyvinyl acetate phthalate. Methacrylic acid copolymer, Type B USP/NFXXII which dissolves at a pH above about 7.0 is preferred. The thickness of the coating is selected to provide the desired release rate depending on the thickness of the coating and the particular coating.

A commercially available copolymer is Eudragit S100 which is based on methacrylic acid and methyl methacrylate and has a weight average molecular weight of about 150,000. Other auxiliary coating aids such as a minor amount (1-5wt% based on the active core component and the total weight of the final coating) of a plasticizer such as acetyltributyl citrate, triacetin, acetylated monoglyceride, rape oil, olive oil, sesame oil, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol (molecular weight of from 380 to 420), propylene glycol and mixtures thereof in combination with an antisticking agent which is selected from the group consisting of an alkaline earth metal stearate, such as magnesium

stearate or calcium stearate, or talc. The antisticking agents can be used alone or in combination. The antisticking agent may be added in an amount which is equivalent to 0.3 to 1.0:1.0 by weight of the methacrylic acid copolymer. These amounts may be varied to obtain the particular release rate that is desired. These components may be added to the methacrylic acid copolymer in combination with appropriate solvents.

The delayed pulse polymeric coated pellet contains an active core which is coated with a polymeric material which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to diltiazem. The delayed pulse polymeric pellet is designed to release not less than 65% and preferably not less than 75% of diltiazem in vitro about 18 hours after the dosage form of the invention is placed in 0.1N HCl. The rate of release for the delayed pulse pellet is sharply increased, i.e. about 3 to 5 times, as compared to the in vitro rate of release of the enteric coated diltiazem pellets of the invention.

The delayed pulse pellets are made by coating the active core component with 15 to 35wt% and preferably from 15 to 30wt% (based on the combined weight of the active core and the total weight of the final coating) of a polymer such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, or an acrylic copolymer which when used in a sufficient amount will cause the delayed pulse pellet to begin to release diltiazem 10 to 12 hours after the ingestion of the dosage form of the invention. Materials such as Eudragit RS 30D; RS 100; NE 30D; RL 30D or RL 100 may be used to prepare the delayed pulse pellet. A preferred material is an acrylate copolymer which has a permeability which is independent of pH. Such a preferred acrylate

copolymer is commercially available as Eudragit RS30D which is available as a 30wt% aqueous dispersion of copolymers of acrylic and methacrylic acid esters, having a number average molecular weight of 150,000 with a low content of quaternary ammonium groups. Other auxiliary coating aids such as a minor amount (2-7wt% based on the active core component and the total weight of the final coating) of a plasticizer such as acetyltributyl citrate, triacetin, acetylated monoglyceride, rape oil, olive oil, sesame oil, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol (molecular weight of from 380 to 420), propylene glycol and mixtures thereof in combination with an antisticking agent which comprises a alkaline earth stearate such as magnesium or calcium stearate alone or in combination with talc in an amount which is equivalent to 0.3 to 0.75:1 by weight of the acrylate copolymer, may be added to the acrylate copolymer in combination with appropriate solvents.

The controlled release diltiazem formulation of the invention will preferably have a dissolution release rate in simulated intestinal fluid (pH7.5) in a USP XXII Type II apparatus at 37°C and 75rpm which substantially corresponds to the following:

- a) from 20 to 50wt% and preferably from 25 to 45wt% of total diltiazem is released after 2 hours;
- b) from 30 to 65wt% and preferably from 35 to 55wt% of total diltiazem is released after 12 hours;
- c) from 60 to 95wt% and preferably from 65 to 90wt% of total diltiazem is released after 18 hours;
- d) not less than 75wt% and preferably not less than 80wt% of total diltiazem is released after 24 hours.

The enteric coated diltiazem beads of the invention will preferably have a dissolution release rate in hydrochloric acid, 0.1N in a USP XXII Type II apparatus at 37°C and 100rpm which substantially
5 corresponds to the following:

- a) from 0 to 20wt% and preferably from 0 to 10wt% of total diltiazem is released after 3 hours;
- b) from 0 to 25wt% and preferably from 0-20wt% of total diltiazem is released after 6 hours.

10 The delayed pulse diltiazem beads of the invention will preferably have a dissolution release rate in hydrochloric acid, 0.1N, in a USP XXII Type II apparatus at 37°C and 100rpm which substantially corresponds to the following:

- 15 a) from 0 to 15wt% and preferably not more than 10% of total diltiazem is released after 12 hours;
- b) from 65 to 90wt% of total diltiazem and preferably 70 to 85wt% is released after 18 hours;
- c) not less than 80wt% of total diltiazem is released
20 after 24 hours.

The enteric polymer pellets of the invention and the delayed pulse polymer membrane coated pellets may be placed in soft or hard gelatin capsules or in other dosage forms such as tablets
25 which contain a cushioning agent to prevent damage to the pellets or the polyethylene glycol based dosage formulation which is disclosed in U.S. 5,458,888, which is incorporated by reference.

Generally the dosage form will contain from
30 about 20 to 50wt% and preferably about 40wt% of the enteric polymer membrane coated pellets and from about 50 to 80wt% and preferably about 60wt% of the delayed pulse polymer coated pellets.

35 DESCRIPTION OF THE PREFERRED EMBODIMENTS

EXAMPLE 1

A diltiazem hydrochloride active pellet (A) having the following formulation was prepared:

5	diltiazem hydrochloride, USP	70.0 wt%	168.0kg
	sugar spheres, NF (30/35)	23.67wt%	56.8kg
10	ethylcellulose, NF (Ethocel 10cps)	5.83wt%	14.0kg
	polysorbate 80 NF	0.5wt%	1.20kg
15	isopropyl alcohol, USP*	*	325.7kg
		100.0	<hr/>
	240.00kg		
	*evaporated during processing		

Add the ethylcellulose in the isopropyl alcohol in a stainless steel tank. The diltiazem hydrochloride (micronized) is added to the ethylcellulose solution with continued agitation for at least 10 minutes with the homogenizer under conditions that avoid the formation of lumps or the introduction of air which will cause foaming. The polysorbate 80 is then added while mixing with a homogenizer. The coating suspension is sprayed onto the sugar spheres in a fluidized bed coater under the following conditions: product temp. 20-35°C; atomization pressure 2-4 bars; air volume 700-1800 m³/L and a pump rate of 300-1500mg/min. After spraying, the pellets are dried in the fluidized bed coater for approximately 10 minutes and then cooled and collected using a particle size separator.

The diltiazem active pellets (A) are then coated with the enteric polymer to form enteric polymer membrane coated diltiazem rapid release pellets as follows:

35	diltiazem HCl Active pellets (A)	93.0wt%	98.58kg
40	methacrylic acid copolymer (Eudragit S100)	4.725t%	5.01kg
	acetyltributyl citrate	0.70wt%	0.74kg
	talc, USP	1.575wt%	1.67kg

isopropyl alcohol, USP	111.0kg
purified water, USP	<u>3.14kg</u>
	100.0wt% 106.0kg

5 The acetyl tributyl citrate is dissolved in the isopropyl alcohol in a stainless steel tank while homogenizing. The Eudragit S-100 is added to the acetyltributyl citrate/isopropyl alcohol solution until it completely dissolves. Purified water is added to the polymer solution to provide a clear solution. Then the talc is dispersed in the solution while mixing until a uniform coating suspension is formed. The solution is continuously stirred throughout the coating process to prevent sedimentation of the talc.

15

Extended release or delayed pulse diltiazem pellets (SR2) are prepared using the following coating suspension:

20	diltiazem HCl active pellets (A)	71.86t%	107.55kg
	acrylic acid copolymer (Eudragit RS30D)	16.406wt%	82.68kg
	acetyltributyl citrate	3.327wt%	4.98kg
25	magnesium stearate	0.250wt%	0.375kg
	talc, USP	8.065wt%	12.07kg
	polysorbate 80	0.092wt%	0.138kg
	purified water, USP*		<u>111.73kg</u>
		100.0wt%	

30 talc (for dusting after coating) 3.00kg
*evaporates during processing

Processing procedures:

1. Add the polysorbate 80 to the purified water while homogenizing for 10 minutes.
- 35 2. Add the magnesium stearate to the solution of the polysorbate 80 and homogenized for 5 minutes.
3. Add the acetyltributyl citrate to the solution above while homogenizing for 3 minutes.

4. Add talc to the dispersion above and mix for 10 minutes.

5. Add the dispersion prepared above into the acrylic polymer dispersion and mix for at least 10 minutes before spray coating the active pellets. Keep stirring during the coating process.

The diltiazem active pellets are loaded into a fluidized bed coater at an inlet temperature of 50°C. The pellets are preheated at a temperature of 50°C for 3 minutes.

The following conditions are used during spray coating: product temperature: first hour; 35-40°C; thereafter 32-35°C; atomization pressure; 3-4 bar; pump rate; first hour: 300-600g/min, then 600-1500g/min.

After all coating suspension is consumed, dry the pellets in the fluidized bed for 5 minutes. Then cool the pellets until the product temperature drops to 25-30°C and discharge the coated pellets while dusting with talc. The pellets are then dried in an oven at 60°C for at least 40 hours.

The resultant pellets are mixed with the rapid release beads in a ratio of 4:6 based on the content of diltiazem HCl. Then, the blended pellets are encapsulated into a hard gelatin capsule to manufacture the diltiazem HCl ER capsules 300mg.

EXAMPLE 2

30 This Example provides an alterative delayed pulse bead formula which is made using the procedure of Example 1:

35	diltiazem HCl active pellets	69.30wt% 120g
	acrylic acid copolymer (Eudragit RS30D)	18.0wt% 103.89g
	talc	8.0wt% 13.85g

magnesium stearate	1.0wt%	1.73g
acetyltributyl citrate	3.6wt%	6.24g
polysorbate 80	0.1wt%	0.18kg

5

COMPARATIVE EXAMPLE 3

This Example provides an alternative delayed pulse bead formula which is made using the procedure of Example 1 without magnesium stearate:

10	diltiazem HCl Active pellets	69.30wt%	120g
	acrylic acid copolymer (Eudragit RS30D)	18.0wt%	103.89g
	talc	9.0wt%	13.85g
	acetyltributyl citrate	3.6wt%	6.24g
15	polysorbate 80	0.1wt%	0.18kg

Where reference is made to a USP Type II apparatus, that apparatus is intended to be the USP dissolution apparatus described in USP XXII which is incorporated by reference.

20

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended
 25 claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

I claim:

1. A once-a-day controlled release formulation of a water soluble drug which comprises:

5 (a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder; and
10 an enteric coating material; and

(b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first
15 layer which consists essentially of a water soluble drug and a binder polymer and a second layer which comprises a polymeric membrane and an alkaline earth metal stearate said second layer being capable of substantially maintaining its integrity in the
20 varying pH conditions of the gastrointestinal tract and being permeable to diltiazem; and

(c) a unit dose containment system.

2. A once-a-day controlled release formulation of a
25 water soluble drug as defined in claim 1 which comprises about 40wt% of (a) and about 60wt% of the pellets of (b).

3. A once-a-day controlled release formulation of a
30 water soluble drug as defined in claim 1 wherein the enteric polymeric coating material is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxypropyl methylcellulose phthalate and cellulose acetate phthalate.

35

4. A once-a-day controlled release formulation of a water soluble drug as defined in claim 1 wherein the

enteric polymeric coating material and the second layer on the delayed pulse pellets both contain a plasticizer.

5 5. A once-a-day controlled release formulation of a water soluble drug as defined in claim 4 wherein the plasticizer is acetyltributyl citrate.

10 6. A once-a-day controlled release formulation of a water soluble drug as defined in claim 3 wherein the membrane on the enteric coating polymeric material is a methacrylic acid copolymer.

15 7. A once-a-day controlled release formulation of a water soluble drug as defined in claim 1 wherein the second layer on the delayed pulse polymeric membrane coated pellets comprises a copolymer of acrylic and methacrylic acid esters with a low content of ammonium groups, magnesium stearate and talc.

20 8. A once-a-day controlled release of a formulation of a water soluble drug as defined in claim 1 which exhibits in 0.1N HCl, a release rate profile which is initially a zero order release rate of the water soluble drug that continues for up to about 12-14
25 hours and thereafter exhibits a sharp increase in the rate of release of said water soluble drug.

30 9. A delayed pulse bead formulation of a water soluble drug which comprises membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a polymeric binder polymer and
35 a second layer which comprises a polymeric membrane, an alkaline earth metal stearate and talc said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the

gastrointestinal tract and being permeable to said water soluble drug and which resists any substantial release of said water soluble drug for 12 hours in a USP dissolution Type II apparatus at 37°C , 100rpm in hydrochloric acid at pH 1.0.

10. A once-a-day controlled release diltiazem formulation which comprises:
- (a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a binder; and a second layer which comprises a membrane comprising an enteric coating material; and
- (b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a combined first layer which consists essentially of diltiazem and a binder polymer and a second layer which comprises a polymeric membrane and an alkaline earth metal stearate said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to diltiazem; and
- (c) a unit dose containment system.

11. A once-a-day controlled release diltiazem formulation as defined in claim 10 which comprises about 40wt% of (a) and about 60wt% of the pellets of (b).

12. A once-a-day controlled release diltiazem formulation as defined in claim 10 wherein the enteric coating polymeric material is selected from the group consisting of shellac, methacrylic acid

copolymers, hydroxy propylmethylcellulose phthalate and cellulose acetate phthalate.

5 13. A once-a-day controlled release diltiazem formulation as defined in claim 10 wherein the enteric coating polymeric material and the second layer on the delayed pulse pellets both contain a plasticizer.

10 14. A once-a-day controlled release diltiazem formulation as defined in claim 13 wherein the plasticizer is acetyltributyl citrate.

15 15. A once-a-day controlled release diltiazem formulation as defined in claim 12 wherein the membrane on the enteric coating polymeric material is a methacrylic acid copolymer.

20 16. A once-a-day controlled release diltiazem formulation as defined in claim 10 wherein the second layer on the delayed pulse polymeric membrane coated pellets comprises a copolymer of acrylic and methacrylic acid esters with a low content of ammonium groups, magnesium stearate and talc.

25 17. A once-a-day controlled release diltiazem formulation as defined in claim 10 which exhibits in 0.1N HCl, a release rate profile which is initially a zero order release rate of diltiazem that continues
30 for up to about 12-14 hours and thereafter exhibits a sharp increase in the rate of release of diltiazem.

35 18. A delayed pulse diltiazem bead formulation which comprises membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a

polymeric binder polymer and a second layer which
comprises a polymeric membrane, an alkaline earth
metal stearate and talc, said second layer being
capable of substantially maintaining its integrity in
5 the varying pH conditions of the gastrointestinal
tract and being permeable to diltiazem and which
resists any substantial release of diltiazem for 12
hours in a USP dissolution Type II apparatus at 37°C
10 , 100rpm in hydrochloric acid at pH 1.0.

10




FIG. 1




FIG. 2




FIG. 3

DILTIAZEM MEAN DATA




FIG. 4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25604

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 9/58, 9/60, 9/62

US CL :424/494, 458, 461, 462, 468, 496, 497; 514/963

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/494, 458, 461, 462, 468, 496, 497; 514/963

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,567,441 A (CHEN) 22 October 1996, see entire document.	1-18
Y	US 5,229,135 A (PHILIPPON et al) 20 July 1993, see entire document.	1-18
Y	US 5,529,791 A (DEBOECK et al) 25 June 1996, see entire document.	1-18

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 JANUARY 2000

Date of mailing of the international search report

07 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN K. SEIDLECK 

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25604

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

BIOSIS, MEDLINE, CAPLUS, USPATFULL, DRUGU, TOXLIT, MEDLINE

search terms: diltiazem, zero order release, bead, beadlet, pellet, controlled release, sustained release